By Cecilia Butini

 

Swiss pharmaceutical major Novartis AG said Thursday that it has entered into an initial agreement with healthcare company Roche Holding AG for the production of the active pharmaceutical ingredient for one of Roche's drugs.

Novartis said the agreement is to reserve capacity and implement a technology transfer for the production of the active pharmaceutical ingredient in Roche's Actemra/RoActemra, a rheumatoid arthritis drug.

As part of the agreement, Roche's manufacturing expertise will be transferred to Novartis's drug-substance site in Singapore during the second quarter of the year, the company said.

The agreement follows similar deals that Novartis struck with BioNTech SE and CureVac NV to provide manufacturing capacity for Covid-19 vaccines.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

April 15, 2021 01:59 ET (05:59 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Novartis Charts.